Clinical trial
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and…
NCT01336634 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT01336634 |
|---|---|
| Title | Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. |
| Official title | A Phase II Study of the BRAF Inhibitor Dabrafenib as a Single Agent and in Combination With the MEK Inhibitor Trametinib in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Dabrafenib, Trametinib |
| Enrollment | 177 |
| Start date | Aug 5, 2011 |
| Primary completion | Oct 1, 2015 |
| Completion | Jan 7, 2021 |
| First posted | Apr 18, 2011 |
| Last update posted | Apr 4, 2022 |
| Countries | France, Germany, Italy, Japan, Netherlands, Norway, South Korea, Spain, Taiwan, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: